Alnylam Pharmaceuticals
Price & Volume
Stats
See moreOpen | $329.09 |
Previous Close | $331.24 |
Day Range | $329.09-$334.48 |
52W Range | $205.87-$495.55 |
Market Cap | $43.4B |
Shares Short | 5M |
Financials
See moreRevenue (12 Mos) | $3.7B |
Revenue Growth (YoY) | 84.9% |
Gross Profit (12 Mos) | $3B |
Diluted EPS | $2.32 |
News
See moreYahoo Finance • 15 days ago
Stock Market Today, Feb. 12: Stocks moderate as initial claims fall, continuing claims rise
Yahoo Finance • 15 days ago
Alnylam: Q4 Earnings Snapshot
Yahoo Finance • 15 days ago
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress
Yahoo Finance • 16 days ago
Pre-Market Earnings Report for February 12, 2026 : BN, HWM, AEP, ZTS, CBRE, EXC, ETR, ALNY, PCG, IRM, FTS, QSR
About
CEO | Dr. Yvonne L. Greenstreet M.B.A., M.D. |
CFO | Mr. Jeffrey V. Poulton M.B.A. |
Address | 675 West Kendall Street, Cambridge, MA, United States, 02142 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 2,500 |
